The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJVirtual | Isavuconazole: primary anti-fungal prophylaxis in AML and MDS
Prithviraj Bose, MD, of The University of Texas MD Anderson Cancer Center, Houston, TX, talks on the use of isavuconazole, an extended spectrum mold-active triazole, investigated as a primary anti-fungal prophylaxis in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), as evaluated in an open-label, prospective, Phase II study. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
